 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Inhaled Insulin with or Instead of Oral Medications for Type 2 Diabetes
18 October 2005 | Volume 143 Issue 8 | Page I-28
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes. A Randomized, Controlled Trial." It is in the 18 October 2005 issue of Annals of Internal Medicine (volume 143, pages 549-558). The authors are J. Rosenstock, B. Zinman, L.J. Murphy, S.C. Clement, P. Moore, C.K. Bowering, R. Hendler, S.-P. Lan, and W.T. Cefalu.
What is the problem and what is known about it so far?
Type 2 diabetes mellitus (adult-onset diabetes) interferes with the body's ability to store energy from food, resulting in high blood sugar levels that can lead to problems, such as kidney failure, blindness, and heart disease. Insulin helps the body to convert food to stored energy and keeps blood sugar levels within the normal range. In type 2 diabetes, body tissues are resistant to the effects of insulin and patients lack effective insulin levels that are required to keep their blood sugar levels normal. Some patients can overcome the abnormalities by taking prescription pills, while others must take insulin injections at least once daily. Researchers have been exploring ways to give insulin to diabetic patients other than by injection. One alternative is inhaled insulin, whereby patients breathe insulin into their lungs by using a special device.
Why did the researchers do this particular study?
To find out whether inhaled insulin improves the control of type 2 diabetes in patients who do not achieve good control with pills alone.
Who was studied?
309 patients with type 2 diabetes who were taking pills and had poorly controlled diabetes. The researchers defined poor control as a hemoglobin A1c level between 8% and 11%. Hemoglobin A1c levels indicate blood sugar levels over the past 3 months. An important goal of diabetes treatment is to lower hemoglobin A1c levels to 7% or less.
How was the study done?
The researchers assigned patients at random to continue taking the diabetes pills, to add inhaled insulin before meals to the pills, or to stop taking the pills and take only inhaled insulin before meals. Study patients adjusted inhaled insulin doses according to blood sugar levels. After 12 weeks, the researchers compared the changes in hemoglobin A1c levels in the 3 groups. They also examined side effects, including weight gain, and episodes during which blood sugar levels were too low.
What did the researchers find?
Improvements in hemoglobin A1c level were best in the group that took inhaled insulin with the pills, second-best in the group that took only inhaled insulin, and worst in the group that took only pills. Mild weight gain, episodes of low blood sugar levels, and mild cough were more frequent in the inhaled insulin groups. Lung function was similar in all groups.
What were the limitations of the study?
The authors did not compare inhaled insulin with injected insulin. In addition, whether patients would continue to show improved blood sugar levels or have side effects if they used inhaled insulin for longer than 12 weeks is not known. Of note, the inhaler device is currently large and allows dosing of 2.5 to 3.0 units of insulin. Injected insulin currently allows for finer adjustments in dose than inhaled insulin.
What are the implications of the study?
Inhaled insulin may be a treatment option for type 2 diabetes when patients do not achieve good control by using pills alone.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. Rosenstock, W. T. Cefalu, P. A. Hollander, A. Belanger, F. G. Eliaschewitz, J. L. Gross, S. S. Klioze, L. B. St. Aubin, H. Foyt, M. Ogawa, et al. Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 2 Diabetes Diabetes Care, September 1, 2008; 31(9): 1723 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jull How to write a commentary an editor's perspective Evid. Based Nurs., October 1, 2007; 10(4): 100 - 103. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Exploring Treatment Strategies for Type 2 Diabetes Diabetes Care, October 1, 2007; 30(10): 2737 - 2745. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Wise, J. G. Teeter, R. L. Jensen, R. D. England, P. F. Schwartz, D. R. Giles, R. C. Ahrens, N. R. MacIntyre, R. J. Riese, and R. O. Crapo Standardization of the Single-Breath Diffusing Capacity in a Multicenter Clinical Trial Chest, October 1, 2007; 132(4): 1191 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Q. Pham, H. Cohen, and V. Chu Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus J. Clin. Pharmacol., July 1, 2007; 47(7): 890 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Mikhail, S. Wali, and D. Cope Effect of Inhaled Insulin on Fasting and Postprandial Plasma Glucose Ann Intern Med, June 5, 2007; 146(11): 821 - 821. [Full Text] [PDF]
|
|
|
|
|
|
L. Ceglia, J. Lau, and A. G. Pittas Effect of Inhaled Insulin on Fasting and Postprandial Plasma Glucose Ann Intern Med, June 5, 2007; 146(11): 821 - 822. [Full Text] [PDF]
|
|
|
|
 |
|
 E. von Kriegstein, K. von Kriegstein, C. A. Guevara, J. L. Gross, R. I. Henkin, G. T. McMahon, and R. A. Arky Inhaled Insulin for Diabetes Mellitus N. Engl. J. Med., May 17, 2007; 356(20): 2106 - 2108. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Skyler, L. Jovanovic, S. Klioze, J. Reis, W. Duggan, and for the Inhaled Human Insulin Type 1 Diabetes Stud Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes Diabetes Care, March 1, 2007; 30(3): 579 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghosh and A. Collier Inhaled insulins Postgrad. Med. J., March 1, 2007; 83(977): 178 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. McMahon and R. A. Arky Inhaled Insulin for Diabetes Mellitus N. Engl. J. Med., February 1, 2007; 356(5): 497 - 502. [Full Text] [PDF]
|
|
|
|
|
|
W. T. Cefalu Point: Pulmonary Inhalation of Insulin: Another "Brick in the Wall" Diabetes Care, February 1, 2007; 30(2): 439 - 441. [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Exubera: inhaled insulin for diabetes DTB, January 1, 2007; 45(1): 5 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J Heine, M Diamant, J-C Mbanya, and D M Nathan Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ, December 9, 2006; 333(7580): 1200 - 1204. [Full Text] [PDF]
|
|
|
|
|
|
L. Ceglia, J. Lau, and A. G. Pittas Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med, November 7, 2006; 145(9): 665 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Meformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea: Response to Mikhail and Cope Diabetes Care, October 1, 2006; 29(10): 2333 - 2334. [Full Text] [PDF]
|
|
|
|
|
|
N. Mikhail and D. Cope An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Meformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea: Response to Barnett et al. Diabetes Care, October 1, 2006; 29(10): 2332 - 2333. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Glibenclamide as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on Metformin Diabetes Care, August 1, 2006; 29(8): 1818 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and B. Zinman Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, August 1, 2006; 29(8): 1963 - 1972. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Murphy and S. Dinneen Inhaled insulin added onto or replacing 2 oral agents reduced haemoglobin A1c concentrations in type 2 diabetes Evid. Based Med., June 1, 2006; 11(3): 77 - 77. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Metformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea. Diabetes Care, June 1, 2006; 29(6): 1282 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bellary and A. H Barnett Review: Inhaled insulin: overcoming barriers to insulin therapy? The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 103 - 108. [Abstract] [PDF]
|
|
|
|
|
|
B. Kanna and N. Mishra Efficacy and Safety of Inhaled Insulin Therapy Ann Intern Med, April 4, 2006; 144(7): 533 - 533. [Full Text] [PDF]
|
|
|
|
|
|
L. Tosiello and P. Ravi Efficacy and Safety of Inhaled Insulin Therapy Ann Intern Med, April 4, 2006; 144(7): 533 - 533. [Full Text] [PDF]
|
|
|
|
|
|
H. Sox Efficacy and Safety of Inhaled Insulin Therapy Ann Intern Med, April 4, 2006; 144(7): 533 - 533. [Full Text] [PDF]
|
|
|
|
|
|
L. J Patrick Inhaled insulin added to or replacing 2 oral agents reduced haemoglobin A1c concentrations in type 2 diabetes Evid. Based Nurs., April 1, 2006; 9(2): 49 - 49. [Full Text] [PDF]
|
|
|
|
|
|
A. Tonks What's new in the other general journals BMJ, October 29, 2005; 331(7523): 987 - 988. [Full Text] [PDF]
|
|
|
|
 |
|
 New Treatments for Uncontrolled Diabetes Journal Watch (General), October 25, 2005; 2005(1025): 1 - 1. [Full Text]
|
|
|
|
|
|
R. J. Comi Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma Ann Intern Med, October 18, 2005; 143(8): 609 - 610. [Full Text] [PDF]
|
|
Read all Rapid Responses
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
